M2 Presswire - FDA Issues Early Communication about an Ongoing Review of Vytorin.
Friday, December 5th, 2008On the eve of a date with congressional investigators, executives from Merck and Schering-Plough acknowledged Monday that their blockbuster cholesterol drug, Vytorin, offered no benefit over Zocor.
The news that Vytorin fell short of an old stand-by statin drug, now sold as a cheap ge…
